DrugPatentWatch Database Preview

Details for Patent: 6,017,922

« Back to Dashboard

Summary for Patent: 6,017,922

Title:	Thermally stable trimetrexates and processes for producing the same
Abstract:	The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P1(#2) and having a triclinic cell with dimensions of about a=7.699 .ANG., b=9.606 .ANG. and c=13.012 .ANG. is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline , is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.
Inventor(s):	Stogniew; Martin (Blue Bell, PA), Grafe; Ingomar (Nurnberg, DE), Morsdorf; Johann (Langenzenn, DE)
Assignee:	U.S. Bioscience, Inc. (Conshohocken, PA)
Application Number:	09/080,290
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 6,017,922
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 6,017,922

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,017,922

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	4081799
Brazil	9910543
Canada	2333274
European Patent Office	1080079
Japan	2002515493